


Product Name : S-217622
Cat. No. : PC-38178
CAS No. : 2647530-73-0
Molecular Formula : C₂₂H₁₇ClF₃N₉O₂
Molecular Weight : 531.884
Target : SARS-CoV-2 Inhibitors
Solubility : 10 mM in DMSO (5.3 mg/mL)



Biological Activity

S-217622 (Ensitrelvir, S217622) is the first oral, non-covalent, non-peptidic **SARS-CoV-2 3C-like protease (3CLpro)** inhibitor clinical candidate with biochemical IC₅₀ of 13 nM, antiviral EC₅₀ of 0.37 μM.

The antiviral activity of S-217622 against SARS-CoV and SARS-CoV-2 was similar especially at the site where homology of 3CLpro was well conserved.

S-217622 also exhibited potent antiviral ability against the Middle East respiratory syndrome (MERS), human coronavirus OC43 (HCoV-OC43), and human coronavirus 229E (HCoV-229E).

S-217622 exhibited no inhibitory effect against host-cell proteases, such as cathepsin B/D/G/L, caspase-2, chymotrypsin, and thrombin at 100 μM.

S-217622 dose-dependently inhibited intrapulmonary replication of SARS-CoV-2 in mice, and currently under clinical investigation for COVID-19.

References

Yuto Unoh, et al. *bioRxiv* 2022.01.26.477782.

Kawaoka Y, et al. *Res Sq.* 2022 Feb 24;rs.3.rs-1375091.

McKimm-Breschkin JL, et al. *Antiviral Res.* 2022 Jan;197:105227.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com